Introduction
============

In the treatment of schizophrenia, poor adherence with antipsychotic medication is known to raise personal burden and economic cost ([@b17-ppa-2-67]) by increasing the risk of relapse, hospitalizations ([@b17-ppa-2-67]; [@b62-ppa-2-67]; [@b23-ppa-2-67]; [@b64-ppa-2-67]; [@b3-ppa-2-67]), and poorer functional outcomes, including arrests and violent behaviors ([@b57-ppa-2-67], [@b58-ppa-2-67]; [@b3-ppa-2-67]). The risk of nonadherence with antipsychotic regimens is affected by factors that are broadly categorized as patient, environment, and treatment-related risk factors ([@b29-ppa-2-67]). Among the treatment-related risk factors is choice of the antipsychotic agent.

Differences between typical and atypical antipsychotics have been extensively studied and are the topic of ongoing debate whether some atypical antipsychotics are more effective than others and whether atypicals are more effective than typical antipsychotics ([@b19-ppa-2-67]; [@b47-ppa-2-67]; [@b27-ppa-2-67]; [@b49-ppa-2-67]). When compared on level of medication adherence, schizophrenia patients treated with typical antipsychotics were often found (Cabeza et al 2001; [@b56-ppa-2-67]; Al-Zarkawi et al 2003; [@b37-ppa-2-67]; [@b38-ppa-2-67]; [@b41-ppa-2-67]; Garcia-Gibson et al 2004), but not always ([@b13-ppa-2-67]; [@b12-ppa-2-67]; [@b23-ppa-2-67]; [@b63-ppa-2-67]), to have poorer adherence compared to patients treated with atypicals. When comparing adherence between atypical agents, several studies reported greater adherence to specific atypical antipsychotics versus other atypicals (eg, to olanzapine vs risperidone) ([@b18-ppa-2-67]; [@b65-ppa-2-67]; [@b41-ppa-2-67]; [@b44-ppa-2-67]; [@b12-ppa-2-67]; [@b21-ppa-2-67]), whereas other studies did not ([@b13-ppa-2-67]; [@b23-ppa-2-67]; [@b63-ppa-2-67]).

In contrast with the inconclusive findings on differential adherence to various antipsychotics, previous findings on medication persistence with antipsychotics have been relatively consistent, often showing better persistence on atypical than typical antipsychotics ([@b46-ppa-2-67]; [@b24-ppa-2-67]; [@b33-ppa-2-67]; [@b34-ppa-2-67]; [@b14-ppa-2-67]; [@b30-ppa-2-67]; [@b4-ppa-2-67]; [@b60-ppa-2-67]; [@b61-ppa-2-67]; [@b6-ppa-2-67]; [@b9-ppa-2-67]; [@b25-ppa-2-67]) and better persistence with a specific atypical (olanzapine) when compared to other atypicals such as risperidone, quetiapine, ziprasidone, and aripiprazole (PhRMA aripiprazole; [@b22-ppa-2-67]; [@b45-ppa-2-67]; [@b5-ppa-2-67]; [@b50-ppa-2-67]; [@b14-ppa-2-67]; [@b42-ppa-2-67]; [@b51-ppa-2-67]; [@b8-ppa-2-67]; [@b39-ppa-2-67]; [@b31-ppa-2-67], [@b32-ppa-2-67]; [@b61-ppa-2-67]; [@b9-ppa-2-67]; [@b25-ppa-2-67]; [@b26-ppa-2-67]; [@b40-ppa-2-67]; [@b53-ppa-2-67]).

Differences in persistence among atypical antipsychotics were also observed in the NIMH-sponsored CATIE schizophrenia study ([@b35-ppa-2-67]; [@b36-ppa-2-67]; [@b55-ppa-2-67]), a large, 18-month, double-blind, randomized study comparing 5 antipsychotics: a medium potency typical antipsychotic (perphenazine) and 4 atypical antipsychotics (olanzapine, risperidone, quetiapine, ziprasidone). Persistence, as measured by time to all-cause medication discontinuation, was assumed to reflect a medication's efficacy, safety, and tolerability from both patient and clinicians' perspectives ([@b54-ppa-2-67]; [@b35-ppa-2-67]). The primary phase of the CATIE, Phase 1, found significantly longer time to all-cause medication discontinuation on olanzapine compared to risperidone and quetiapine. Treatment duration on olanzapine did not significantly differ from ziprasidone or perphenazine as the initially significant differences favoring olanzapine turned nonsignificant following adjustment for multiple comparisons. In a second phase of CATIE (phase 2E; [@b36-ppa-2-67]), which included patients who discontinued Phase 1 due to lack of medication efficacy, persistence in therapy was significantly longer for clozapine than quetiapine or risperidone, but not compared to olanzapine. Furthermore, in CATIE phase 2T ([@b55-ppa-2-67]), which included patients who discontinued Phase 1 due to medication intolerability or lack of efficacy, persistence in therapy was longer for patients treated with risperidone and olanzapine compared to quetiapine and ziprasidone. In addition, for patients who discontinued their previous anti-psychotic because of inefficacy, persistence on olanzapine therapy was longer than for quetiapine and ziprasidone and for risperidone longer than quetiapine.

Although adherence and persistence with antipsychotics have been extensively examined using multiple methodologies, they have been studied separately in different patient populations ([@b9-ppa-2-67]). As a result, no information is available on the potential correspondence between patients' adherence and persistence on the same medications in the treatment of schizophrenia. The only study that assessed both persistence and adherence with atypical antipsychotics in the same population ([@b9-ppa-2-67]) did not assess concordance between the adherence and persistence measures and focused on adherence with specific atypical antipsychotics among patients who were deemed persistent with any atypical antipsychotic regimen. That study found differential persistence among the atypicals (greater likelihood of persistence with clozapine and olanzapine than with risperidone), but no differentiation on adherence among the persistent patients.

The present study aimed to expand on previous research and assess differences in medication adherence and persistence to typical versus atypical antipsychotics and to specific atypical agents in the usual care of patients with schizophrenia. A secondary objective was to examine the concordance between patients' adherence and persistence with the same antipsychotics. Using prescription data from a large, 3-year prospective, naturalistic, nonrandomized, noninterventional, multisite study of patients treated for schizophrenia in the US, we identified patients who were initiated on typical (haloperidol) or atypical (clozapine, olanzapine, risperidone, or quetiapine) antipsychotics at any time in the study and had been followed up for at least 1 year post-initiation. We expected adherence and persistence to be highly interrelated, and based on previous research on persistence with antipsychotics in the treatment of schizophrenia ([@b22-ppa-2-67]; Ren et al 2000; [@b5-ppa-2-67]; [@b34-ppa-2-67]; [@b33-ppa-2-67]; [@b50-ppa-2-67]; [@b42-ppa-2-67]; [@b51-ppa-2-67]; [@b14-ppa-2-67]; [@b8-ppa-2-67]; [@b35-ppa-2-67]; [@b55-ppa-2-67]; [@b36-ppa-2-67]; [@b31-ppa-2-67], [@b32-ppa-2-67]; [@b61-ppa-2-67]; [@b60-ppa-2-67]; [@b25-ppa-2-67]; [@b9-ppa-2-67]; [@b40-ppa-2-67]) we hypothesized that the 4 atypicals are superior to the typical antipsychotic haloperidol on persistence and adherence and that clozapine and olanzapine therapy would differentiate themselves among the 4 atypical agents with greater adherence and persistence.

Methods
=======

Data source
-----------

We used data from the Lilly-sponsored Schizophrenia Care and Assessment Program (US-SCAP), a large (n = 2327), 3-year, naturalistic, prospective, nonrandomized noninterventional study in the US that was conducted between 7/1997 and 9/2003 ([@b16-ppa-2-67]; [@b2-ppa-2-67], [@b3-ppa-2-67], [@b4-ppa-2-67]). The goal of US-SCAP was to understand the treatment of patients with schizophrenia in "real world" settings. Approximately 400 patients at each of the study's 6 regional sites were enrolled. All patients were diagnosed with schizophrenia, schizoaffective, or schizophreniform disorders based on DSM-IV criteria and were at least 18 years of age. Patients were excluded if they were unable to provide informed consent or had participated in a clinical drug trial within 30 days prior to enrollment. Of 3332 patients who met inclusion criteria, 765 (23.0%) refused, and 240 (7.2%) were not enrolled due to other reasons. Most enrollees completed 1 year of follow-up (78.1%), with fewer patients completing 2 years (69.6%) and 3 years (65.2%).

Enrollment was not contingent upon being treated with a specific antipsychotic or with any medication. Patients could continue with medications they were prescribed prior to enrollment for as long as necessary, and decisions about changes in medications during the study, if any, were made by physicians and their patients as occurs in usual practice.

Patients were enrolled from 6 states (California, Colorado, Connecticut, Florida, Maryland, and North Carolina) and represented treatment in diverse systems of care including community mental health centers, university health care systems, the Department of Veterans Affairs Health Services (VA), and community and state hospitals. Institutional Review Board (IRB) approval was received at each regional site, and informed consent was received from all patients. Further details about US-SCAP are available elsewhere ([@b16-ppa-2-67]; [@b3-ppa-2-67], [@b4-ppa-2-67]).

The present study included patients who were initiated at any time during the 3-year study on haloperidol, clozapine, risperidone, olanzapine, or quetiapine in standard oral formulation. Treatment group membership was based on the first initiated medication at any time in the study. These patients did not receive the index medication in the 60 days prior to initiation and had at least 1 year of follow-up after initiation. Reflecting usual clinical practice, patients could be augmented with other typical and/or atypical antipsychotics (antipsychotic polypharmacy), in any formulation at any time per physician's decision. Patients initiated on ziprasidone or aripiprazole were excluded from the analysis due to small sample size.

Measures
--------

Interviews with the patients at enrollment provided information about socio-demographic characteristics and psychiatric history. Starting at enrollment, medical records were systematically abstracted for each prior 6-month interval for every patient using a medical resource abstraction form that was developed for this study.

Patients' medical records provided information about each psychiatric hospitalization (admission and discharge dates) and about prescribed psychiatric medication (medication name, dose, frequency, start and stop dates, and route of administration). Patients were queried about use of medications and other psychiatric resources outside of those provided at their regular treatment site. When this occurred, systematic efforts were made to abstract out-of-site medical records.

Consistent with prior research ([@b62-ppa-2-67]; [@b64-ppa-2-67]), adherence was assessed with the Medication Possession Ratio (MPR), the percent of total cumulative days with the index medication during the 365 days following its initiation. Higher values indicate better adherence with the prescribed antipsychotic medication. Poor adherence, often defined as MPR ≤80%, was previously found to be associated with a high risk of psychiatric hospitalizations ([@b62-ppa-2-67]; [@b59-ppa-2-67]; [@b3-ppa-2-67]), emergency services, arrests, violent behaviors, substance use, and other unfavorable outcomes ([@b59-ppa-2-67]; [@b3-ppa-2-67]). Adherence was defined as MPR \>80%, a threshold used in past research to assess adherence with antipsychotics in the treatment of schizophrenia ([@b13-ppa-2-67]; [@b23-ppa-2-67]; [@b62-ppa-2-67], [@b63-ppa-2-67]; [@b15-ppa-2-67]). The MPR was used to calculate mean adherence rates (continuous MPR) and the proportion of adherent patients (MPR \>80%) in each treatment group.

Although MPR is commonly used to quantify medication use in pharmacy claims databases, the MPR in this study was based on prescription information in medical records. Since no pharmacy claim data were collected in US-SCAP, the rate of prescription fill is unknown. However, prior research in this population ([@b56-ppa-2-67]) has shown a high level of correspondence between medication prescription in medical records and pharmacy fill rate.

Persistence with the index antipsychotic drug was defined as the time to medication discontinuation for any cause and calculated as the number of consecutive days from initiation of the index drug to the start of the first medication gap of \>30 days during the 1-year following initiation ([@b45-ppa-2-67]; [@b65-ppa-2-67]; [@b38-ppa-2-67]; [@b21-ppa-2-67]). A gap could have resulted from any number of events, including switching to another drug or discontinuation of the drug. Although several studies have used the criterion of \>14 consecutive days without medication as an indicator of drug discontinuation, we took a more conservative approach and used a larger medication gap size. Past research has shown consistent findings when using 14 or 30 days to define medication discontinuation in the treatment of schizophrenia ([@b4-ppa-2-67]). In addition to mean time to medication discontinuation, the proportion of patients completing at least 1 year of treatment on the initiated antipsychotic was also measured.

Statistical analysis
--------------------

Group comparisons on socio-demographic and treatment characteristics prior to initiation on the "index" antipsychotic medication were made using chi-square tests for categorical variables and ANOVA for continuous variables. To compare medication groups on adherence, we performed linear and logistic regression models after square root transformation of the MPR due to its skewed distribution ([@b7-ppa-2-67]). These analyses controlled for patient socio-demographics (age, sex, ethnicity), illness duration, and treatment variables on which the treatment groups were found to significantly differ during the 2 months prior to initiation of the index medication (psychiatric hospitalization \[yes/no\] and use \[yes/no\] of: oral antipsychotics, depot typical antipsychotics, mood stabilizers, and antipsychotic polypharmacy). To check the robustness of the findings, analyses were repeated controlling also for potential "time period bias" in the regression analysis, because atypical antipsychotics were introduced in the US over several years. To that end, we calculated for each patient the time (days) elapsed between the study start (7/1/1997) and the initiation date on the index medication.

Treatment group comparisons on the mean continuous MPR, proportion of adherent patients per MPR \>80%, mean time to medication discontinuation for any cause, and proportion of patients completing at least 1 year on the index medication were performed for the typical (haloperidol) versus atypicals (clozapine, risperidone, olanzapine, quetiapine, combined), for the typical versus each of the 4 atypicals, and pair-wise comparisons between the atypicals. To compare medication groups on the proportion of adherent patients (MPR \>80%), we used logistic models with adjustments for covariates noted above. To assess the robustness of the findings, we repeated the latter analysis using 7 other adherence thresholds that dichotomized the MPR into adherent and nonadherent, including MPR \>60%, 65%, 70%, 75%, 85%, 90%, and 95%.

To assess the concordance between the adherence and persistence measures, we calculated Pearson product-moment correlation between the continuous MPR measure and time (days) to all-cause medication discontinuation. Treatment group comparisons on persistence levels employed Cox Proportional Hazard Model, adjusted for covariates used in the adherence analyses.

Although all patients have undergone clinical assessments with standard measures at enrollment and every 12 months thereafter, these assessments were not set to coincide with the time of initiation or discontinuation of any drug. These clinical measures were not used in this study to control for treatment group differences, because the assessments did not reflect patients' clinical status at the time of initiation on the medication. All statistical tests were 2-tailed, and significance was set at alpha of 0.05.

Results
=======

Patient characteristics
-----------------------

This study included patients (n = 878) who were initiated on haloperidol (n = 110), clozapine (n = 74), risperidone (n = 235), olanzapine (n = 347), and quetiapine (n = 112). At the time of initiation on the index medication, the treatment groups significantly differed on age, ethnicity, illness duration, and on the following variables in the 60 days prior to initiation on the index antipsychotic: psychiatric hospitalization, use of antipsychotics in oral formulation, antipsychotics in depot formulation, antipsychotic polypharmacy, and mood stabilizers ([Table 1](#t1-ppa-2-67){ref-type="table"}). Treatment groups also differed on time to initiation on the index medication from the date of the study start. Expectedly, quetiapine-treated patients had longer time to medication initiation since quetiapine was launched in the US later (1997) than clozapine (1990), risperidone (1994), and olanzapine (1996). The mean daily doses (SD) of the index antipsychotics were: 8.8 mg (6.8 mg) for haloperidol, 368.9 mg (164.2 mg) for clozapine, 4.1 mg (2.4 mg) for risperidone, 13.7 mg (7.3 mg) for olanzapine, and 331.6 mg (210.9 mg) for quetiapine.

Adherence
---------

### Mean MPR

The mean MPR for all patients was 70.9%. As presented in [Table 2](#t2-ppa-2-67){ref-type="table"}, the mean MPR was significantly higher for patients treated with atypical antipsychotics (MPR = 73.6%) compared to haloperidol (MPR = 52.0%, p \< 0.001) and for patients treated with each atypical compared to haloperidol (p \< 0.001). Significantly higher mean adherence rate was found for patients treated with clozapine (MPR = 83.5%) compared to risperidone (MPR = 70.0%, p = 0.024) and quetiapine (MPR = 66.2%, p = 0.022). Significantly higher mean adherence rate was found for patients treated with olanzapine (MPR = 76.3%) compared to risperidone (MPR = 70.0%, p = 0.008) and quetiapine (MPR = 66.2%, p = 0.005). Differences between risperidone and quetiapine (p = 0.538) and between clozapine and olanzapine (p = 0.648) therapy were not statistically significant.

### Proportion of adherent patients

Overall, 58% of the patients were deemed adherent (MPR \> 80%). A significantly greater proportion of atypical antipsychotic-treated patients were adherent compared to the haloperidol-treated group (61.1% vs 34.5%, p \< 0.001) ([Table 2](#t2-ppa-2-67){ref-type="table"}). Among the atypical agents, a significantly larger proportion of clozapine-treated patients were adherent compared to risperidone (77.0% vs 56.6%, p \< 0.01) and quetiapine (77.0% vs 51.8%, p \< 0.01), but not compared to olanzapine (77.0% vs 63.7%, p \> 0.05). A significantly larger proportion of olanzapine-treated patients were adherent compared to patients treated with risperidone (63.7% vs 56.6%, p = 0.027) and quetiapine (63.7% vs 51.8%, p = 0.019). The difference between risperidone and quetiapine-treated patients was not statistically significant (56.6% vs 51.8%, p = 0.305).

### Sensitivity analyses

To assess robustness of the findings, we repeated the analysis using 7 additional MPR thresholds to define adherence with cutoff values ranging from MPR \>60% to MPR \>95% in 5% increments. [Table 3](#t3-ppa-2-67){ref-type="table"} presents the proportion of adherent patients by treatment group and the associated p values from the logistic regression, demonstrating the robustness of the findings across the 8 variations on the definition of adherence. Results were also essentially unchanged when the analyses were repeated with additional control for potential "time period bias".

Persistence
-----------

Mirroring the adherence-related findings ([Table 2](#t2-ppa-2-67){ref-type="table"}), persistence, as measured by time to all-cause medication discontinuation (days), was significantly shorter for haloperidol (173.9) than for the combined atypical antipsychotic treatment groups (260.7, p ≤ 0.001) and differed between the atypical antipsychotics in descending order: clozapine (305.46), olanzapine (271.66), risperidone (245.07), and quetiapine (230.19). The same descending order was found when using the proportion of patients completing at least 1 year of treatment on the initiated medication: clozapine (71.6%), olanzapine (56.5%), risperidone (48.5%), quetiapine (45.5%), and haloperidol (22.7%). The proportion of patients completing at least 1 year of treatment on the index medication was significantly higher for patients treated with atypicals, in aggregate, compared to the typical (p \< 0.001), and for clozapine compared to halo-peridol (p \< 0.001), risperidone (p = 0.002), and quetiapine (p = 0.004), but not compared to olanzapine (p = 0.052). The olanzapine group had a significantly higher treatment completion rate compared to haloperidol (p \< 0.001), risperidone (p = 0.033), and quetiapine (p = 0.029). The risperidone group had significantly higher treatment completion rates than haloperidol (p \< 0.001), but not compared to quetiapine (p = 0.313). The quetiapine significantly differed only from haloperidol (p = 0.015).

Using the Cox Proportional Hazard Model, the haloperidol-treated group was found to be more likely to discontinue the medication compared to the atypical-treated patients (hazard ratio \[HR\] = 2.31, 95% confidence interval \[CI\] 1.78--3.01, p \< 0.001). The olanzapine-treated patients were more likely to discontinue than clozapine (HR = 1.65, 95% CI 1.01--2.71, p = 0.047). The risperidone-treated patients were more likely to discontinue than clozapine (HR = 2.09, 95% CI 1.29--3.40, p = 0.003) and olanzapine-treated patients (HR = 1.35, 95% CI 1.04--1.74, p = 0.023). The quetiapine-treatment group was more likely to discontinue medication compared to clozapine (HR = 2.24, 95% CI 1.29--3.88, p = 0.004) and olanzapine-treated patients (HR = 1.55, 95% CI 1.09--2.20, p = 0.014). Hazard ratios were statistically significant except for the comparison between risperidone and quetiapine (HR = 1.21, 95% CI 0.86--1.70, p = 0.285).

Adherence and persistence
-------------------------

The MPR-based adherence measure was highly and significantly correlated with the persistent measure -- time to all-cause medication discontinuation (r = 0.957, n = 878, p \< 0.001).

Discussion
==========

In this large, prospective, naturalistic, nonrandomized study of schizophrenia patients, as in several other studies ([@b17-ppa-2-67]; [@b10-ppa-2-67]; [@b23-ppa-2-67]), only about half of the patients (58%) were found to be adherent to antipsychotic regimens. Adherence was, however, especially poor for patients treated with the typical antipsychotic haloperidol. Only 35% of the patients treated with haloperidol were found to be adherent compared to 61% of the patients treated with atypicals. The atypicals were not all alike, and among the studied atypicals, clozapine therapy was associated with highest rate of adherence (77%) followed by olanzapine (64%), risperidone (57%), and quetiapine (52%) therapy. Although rates of adherence with atypicals appear significantly higher than with the typical antipsychotic, these are still suboptimal adherence rates, as a large proportion of the patients remain poorly adherent with their medication regimens.

In addition to replicating previous findings ([@b56-ppa-2-67]; Al-Zarkawi et al 2003; [@b37-ppa-2-67]; Mojtabie et al 2003; [@b41-ppa-2-67]; [@b21-ppa-2-67]), our study expands the literature by showing differential adherence among 4 atypical agents and a descending order in adherence levels: clozapine, olanzapine, risperidone, and quetiapine, with similar and intermediate levels of adherence for risperidone- and quetiapine-treated patients. Moreover, haloperidol was associated with the poorest level of adherence and persistence despite its use in moderate doses (mean dose 8.8 mg/day). This is of interest because most industry-sponsored clinical trials have compared atypical antipsychotics with haloperidol in higher doses, a practice that was considered by some ([@b19-ppa-2-67]; [@b48-ppa-2-67]) to have biased the results in favor of the newer agents. The present findings appear consistent with the meta-analysis by [@b11-ppa-2-67], which showed that the dose of haloperidol did not bias the findings that favored the atypicals over the typicals.

While haloperidol was prescribed in moderate doses, quetiapine was prescribed in relatively low doses (mean 331.6 mg/day). This dose appears, however, to reflect medication use pattern of quetiapine in usual practice in the US. This was previously shown in a large claims database study of schizophrenia patients treated in the US ([@b20-ppa-2-67]) that was sponsored by the manufacturer of quetiapine. Using 7017 treatment episodes during a period from January 1999 through August 2003, the study reported the mean dose of quetiapine to be 264 mg/day, suggesting that our findings reflect usual treatment pattern with quetiapine in the US, at least during the study period.

Although the current adherence-related findings are consistent with several previous studies, they are also inconsistent with some others ([@b13-ppa-2-67]; [@b52-ppa-2-67]; [@b23-ppa-2-67]; [@b63-ppa-2-67]; [@b28-ppa-2-67]; [@b20-ppa-2-67]). The reasons for the inconsistent findings are unclear, but may stem from methodological issues such as differences in adherence measures, study designs, patient populations, cross-sectional approach that compares treatment groups independently of the time of initiation on the medication, lack of uniform period of follow-up, and use of different approaches to controlling for selection effects, and the potential pre-existing differences between the treatment groups.

The present study also shows -- for the first time -- a high and significant level of concordance between adherence and persistence with the medication in the same population, suggesting that the two measures may be interchangeable. It is unclear, however, if both parameters are indeed measuring the same thing, since we used a proxy measure of adherence (did not observe if patients were taking the medications as directed in the prescribed dosage, schedule, and method of ingestion) and did not assess medication acceptance, which may impact both adherence and persistence.

Mirroring results from the adherence-based analyses, persistence level was poorer with haloperidol compared to the four combined atypicals with a similar descending order in persistence levels: clozapine, olanzapine, risperidone, quetiapine, and haloperidol, and with similar and intermediate levels of persistence for the risperidone- and quetiapine-treatment groups. These findings are consistent with previous research demonstrating better persistence with clozapine ([@b4-ppa-2-67]; [@b36-ppa-2-67]; [@b25-ppa-2-67]) compared to olanzapine, risperidone, quetiapine, and typical antipsychotics and better persistence with olanzapine compared to haloperidol ([@b46-ppa-2-67]; [@b24-ppa-2-67]; [@b45-ppa-2-67]; [@b34-ppa-2-67]; [@b14-ppa-2-67]; [@b60-ppa-2-67]; [@b4-ppa-2-67]; [@b61-ppa-2-67]), risperidone ([@b22-ppa-2-67]; [@b5-ppa-2-67]; [@b33-ppa-2-67]; [@b50-ppa-2-67]; [@b14-ppa-2-67]; [@b42-ppa-2-67]; [@b8-ppa-2-67]; [@b35-ppa-2-67]; [@b4-ppa-2-67]; [@b6-ppa-2-67]; [@b9-ppa-2-67]; [@b25-ppa-2-67]; [@b26-ppa-2-67]; [@b61-ppa-2-67]; [@b6-ppa-2-67]; [@b25-ppa-2-67]), and quetiapine ([@b14-ppa-2-67]; [@b35-ppa-2-67]; [@b4-ppa-2-67]; [@b32-ppa-2-67]; [@b36-ppa-2-67]; [@b55-ppa-2-67]; [@b6-ppa-2-67]; [@b25-ppa-2-67]; [@b40-ppa-2-67]). Furthermore, as we hypothesized based on CATIE phase 1 findings ([@b35-ppa-2-67]), no significant differences were found on persistence or adherence between the risperidone and quetiapine treatment groups.

The observed concordance between adherence and persistence with antipsychotics has important ramifications for schizophrenia research and for clinical practice due to growing recognition that persistence with antipsychotics is a global proxy measure of a medication's effectiveness ([@b35-ppa-2-67]) and more importantly because both medication adherence and persistence are associated with beneficial outcomes in the long-term treatment of patients with schizophrenia. Furthermore, the favorable outcomes associated with medication adherence are likely applicable to findings of persistence studies. This extrapolation needs, however, to be further studied across adherence measures, beyond the MPR measure.

The strengths of our study appear to lie in its large, diverse, and representative sample; the ability to provide comparative data on a number of commonly used antipsychotics; the availability of medication information during hospitalizations (a type of data that is typically absent in claims databases); and notably, the ability to generalize the findings to patients treated in large public systems of care across the US.

Our study has, however, a number of limitations. First is the potential for selection bias due to the naturalistic, nonrandomized design of the study in which the treatment groups significantly differed on a number of variables at the time of initiation of the medication. Despite our use of statistical adjustments for observed group differences, other residual imbalances due to unobservable factors could have been present and hampered the comparisons. Although we cannot eliminate the possibility of selection bias, it is important to note that the current findings are consistent with a large body of prior research -- about 29 studies -- that differs in study design and world geographies and include the NIMH-sponsored CATIE ([@b35-ppa-2-67]; [@b36-ppa-2-67]; [@b55-ppa-2-67]) as well as other randomized, double-blind, controlled trials in which selection bias is largely eliminated ([@b46-ppa-2-67]; [@b50-ppa-2-67]; [@b30-ppa-2-67]; [@b6-ppa-2-67]; [@b26-ppa-2-67]; [@b31-ppa-2-67], [@b32-ppa-2-67]).

Lack of information about the reasons for medication discontinuation is another study limitation. Our study was not designed to assess reasons for initiation or discontinuation of the antipsychotic medications, thus lacking this clinically important information. It is notable, however, that time to medication discontinuation for any cause was chosen by the NIMH-Sponsored CATIE trials to be the primary outcome measure, as this global index is said to reflect a medication efficacy, safety, and tolerability from both patient and clinician perspectives ([@b54-ppa-2-67]; [@b35-ppa-2-67]).

Another study limitation is the use of prescription, rather than pharmacy fill data to assess adherence and persistence. Previous research ([@b56-ppa-2-67]) has demonstrated, however, a high level of agreement between prescription rate and pharmacy fill rate in this severely ill population. Moreover, several MPR findings in the present prescription-based study were consistent with pharmacy fill-based MPR findings in previous studies ([@b56-ppa-2-67]; [@b65-ppa-2-67]; [@b41-ppa-2-67]; [@b44-ppa-2-67]; [@b21-ppa-2-67]), suggesting that the two measures are highly correlated. Of special note is a study of Michigan Medicaid pharmacy database ([@b21-ppa-2-67]) showing higher adherence rates for olanzapine- than risperidone-treated patients (60% vs 54%, p \< 0.01), a finding that was almost identical to ours (63.7% vs 56.6%, p \< 0.05). That study also reported an adherence rate on haloperidol (37%) that was very similar to that found in the current study (34.5%). Thus, although the current analysis used prescription data, results were similar to those based on pharmacy fill data, helping to bolster confidence in the validity of the current findings. An additional study limitation is lack of control for potential "sponsor" bias that could have influenced clinicians' medication use patterns in favor of the sponsor's antipsychotic medication (olanzapine). Although we cannot rule out this possibility, the results of the present study are consistent with previous results reported by researchers who used nonindustry-sponsored data such as Medicaid claims databases ([@b41-ppa-2-67]; [@b44-ppa-2-67]; [@b21-ppa-2-67]) and with results from independent, nonindustry-sponsored studies ([@b22-ppa-2-67]; [@b5-ppa-2-67]; [@b33-ppa-2-67]; [@b30-ppa-2-67]; [@b35-ppa-2-67]; [@b9-ppa-2-67]).

Current findings demonstrate that atypical agents are not all alike on medication adherence and persistence suggesting that the choice of antipsychotic agent may be an important factor that impacts treatment adherence and persistence, thus the long-term treatment outcomes during usual care of patients with schizophrenia. Although this study found better adherence and persistence with atypicals, and among the atypicals with clozapine and olanzapine, it is important to note that at its best the overall level of adherence (and persistence) with the medication was still suboptimal, thus requiring diligent identification of the poorly adherent patients and the provision of relevant and effective adherence interventions to help enhance these patients' long-term outcomes. Current findings are based on a large and diverse group of patients that varied in health care delivery systems, geography, ethnicity, gender, and illness severity, a diversity that may facilitate generalization of the findings to schizophrenia patients treated across the US. Future studies are needed to replicate the findings and to identify the reasons that drive better adherence and persistence with specific antipsychotics in order to help tailor individualized adherence improvement strategies for patients who are poorly adherent with their antipsychotic regimens.
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###### 

Patient characteristics by treatment group[a](#tfn1-ppa-2-67){ref-type="table-fn"}

  Characteristic                                                                                                           Haloperidol n = 110   Risperidone n = 235   Olanzapine n = 347   Quetiapine n = 112   Clozapine n = 74
  ------------------------------------------------------------------------------------------------------------------------ --------------------- --------------------- -------------------- -------------------- ------------------
  Age, mean (SD)[b](#tfn2-ppa-2-67){ref-type="table-fn"}                                                                   37.9 (9.6)            41.8 (12.5)           43.3 (10.8)          40.6 (11.2)          38.6 (8.9)
  Illness duration in years, mean (SD)[b](#tfn2-ppa-2-67){ref-type="table-fn"}                                             18.5 (10.9)           21.3 (12.6)           23.3 (11.8)          19.6 (11.1)          20.0 (10.1)
  Male (%)                                                                                                                 55.5                  54.9                  61.1                 47.3                 62.2
  Race (%)[b](#tfn2-ppa-2-67){ref-type="table-fn"}                                                                                                                                                               
   White                                                                                                                   30.9                  46.8                  49.9                 50.9                 62.2
   Black                                                                                                                   48.2                  38.7                  38.3                 35.7                 23.0
   Other                                                                                                                   20.9                  14.5                  11.8                 13.4                 14.9
  High school education or less (%)                                                                                        59.1                  69.2                  65.3                 74.6                 73.0
  Diagnosis (%)                                                                                                                                                                                                  
   Schizoaffective                                                                                                         34.6                  32.8                  32.3                 39.3                 35.1
   Schizophrenia, paranoid                                                                                                 36.4                  38.7                  42.9                 32.1                 40.5
   Schizophrenia, undifferentiated                                                                                         19.1                  16.2                  15.9                 15.2                 18.9
   Other                                                                                                                   10.0                  12.3                  8.9                  13.4                 5.41
  Health Insurance (%)                                                                                                                                                                                           
   Medicaid/Medicare/Medicaid and Medicare                                                                                 76.9                  79.8                  81                   83.6                 86.5
   CHAMPUS (Department of Defense)                                                                                         4.6                   5.6                   7.9                  2.7                  5.4
   Privately insured                                                                                                       5.6                   3.9                   2.6                  2.7                  1.4
   Other                                                                                                                   1.9                   1.3                   0.6                  1.8                  1.4
   No insurance                                                                                                            11.1                  9.4                   7.9                  9.1                  5.4
  Time to initiation on index medication, mean days (S.D.)[b](#tfn2-ppa-2-67){ref-type="table-fn"}                         515.6 (340.9)         640.5 (327.1)         599 (333.1)          834.3 (315.3)        618.7 (349.4)
  Prior psychiatric hospitalization (%)[b](#tfn2-ppa-2-67){ref-type="table-fn"},[c](#tfn3-ppa-2-67){ref-type="table-fn"}   38.2                  22.6                  17.0                 15.2                 35.1
  Prior medication Use[c](#tfn3-ppa-2-67){ref-type="table-fn"}                                                                                                                                                   
   Oral antipsychotics[b](#tfn2-ppa-2-67){ref-type="table-fn"}                                                             43.6                  70.6                  71.5                 88.4                 82.4
   Typical depot antipsychotics[b](#tfn2-ppa-2-67){ref-type="table-fn"}                                                    33.6                  16.6                  21.3                 13.4                 21.6
   Mood stabilizers[b](#tfn2-ppa-2-67){ref-type="table-fn"}                                                                29.1                  20.9                  31.7                 37.5                 37.8
   Antipsychotic polypharmacy[b](#tfn2-ppa-2-67){ref-type="table-fn"}                                                      8.2                   11.1                  6.1                  24.1                 24.3

Percentages listed unless otherwise specified.

Significant groups difference at p \< 0.05.

During the 60 days prior to initiation on the index drug.

###### 

Adherence and persistence in the 1-year post initiation by treatment group

  Treatment group              Adherence                                             Persistence                                                                                             
  ---------------------------- ----------------------------------------------------- ---------------------------------------------- -------------------------------------------------------- ----------------------------------------------
  Atypicals, combined vs HAL   73.6 (35.0)[c](#tfn8-ppa-2-67){ref-type="table-fn"}   61.1[c](#tfn8-ppa-2-67){ref-type="table-fn"}   260.7 (136.0)[c](#tfn8-ppa-2-67){ref-type="table-fn"}    53.9[c](#tfn8-ppa-2-67){ref-type="table-fn"}
                               52.0 (37.9)                                           34.5                                           173.9 (144.5)                                            22.7
  CLO vs OLZ                   83.5 (31.6)                                           77                                             305.46 (114.4)                                           71.6
                               76.3 (33.3)                                           63.7                                           271.7 (129.7)                                            56.5
  CLO vs RIS                   83.5 (31.6)[a](#tfn6-ppa-2-67){ref-type="table-fn"}   77[b](#tfn7-ppa-2-67){ref-type="table-fn"}     305.46 (114.4)[b](#tfn7-ppa-2-67){ref-type="table-fn"}   71.6[b](#tfn7-ppa-2-67){ref-type="table-fn"}
                               70.0 (36.5)                                           56.6                                           245.1 (142.2)                                            48.5
  CLO vs QUE                   83.5 (31.6)[a](#tfn6-ppa-2-67){ref-type="table-fn"}   77[b](#tfn7-ppa-2-67){ref-type="table-fn"}     305.46 (114.4)[b](#tfn7-ppa-2-67){ref-type="table-fn"}   71.6[b](#tfn7-ppa-2-67){ref-type="table-fn"}
                               66.2 (37.0)                                           51.8                                           230.2 (145.2)                                            45.5
  CLO vs HAL                   83.5 (31.6)[c](#tfn8-ppa-2-67){ref-type="table-fn"}   77[c](#tfn8-ppa-2-67){ref-type="table-fn"}     305.46 (114.4)[c](#tfn8-ppa-2-67){ref-type="table-fn"}   71.6[c](#tfn8-ppa-2-67){ref-type="table-fn"}
                               52.0 (37.9)                                           34.5                                           173.9 (144.5)                                            22.7
  OLZ vs RIS                   76.3 (33.3)[b](#tfn7-ppa-2-67){ref-type="table-fn"}   63.7[a](#tfn6-ppa-2-67){ref-type="table-fn"}   271.7 (129.7)[a](#tfn6-ppa-2-67){ref-type="table-fn"}    56.5[a](#tfn6-ppa-2-67){ref-type="table-fn"}
                               70.0 (36.5)                                           56.6                                           245.1 (142.2)                                            48.5
  OLZ vs QUE                   76.3 (33.3)[b](#tfn7-ppa-2-67){ref-type="table-fn"}   63.7[a](#tfn6-ppa-2-67){ref-type="table-fn"}   271.7 (129.7)[b](#tfn7-ppa-2-67){ref-type="table-fn"}    56.5[a](#tfn6-ppa-2-67){ref-type="table-fn"}
                               66.2 (37.0)                                           51.8                                           230.2 (145.2)                                            45.5
  OLZ vs HAL                   76.3 (33.3)[c](#tfn8-ppa-2-67){ref-type="table-fn"}   63.7[c](#tfn8-ppa-2-67){ref-type="table-fn"}   271.7 (129.7)[c](#tfn8-ppa-2-67){ref-type="table-fn"}    56.5[c](#tfn8-ppa-2-67){ref-type="table-fn"}
                               52.0 (37.9)                                           34.5                                           173.9 (144.5)                                            22.7
  RIS vs QUE                   70.0 (36.5)                                           56.6                                           245.1 (142.2)                                            48.5
                               66.2 (37.0)                                           51.8                                           230.2 (145.2)                                            45.5
  RIS vs HAL                   70.0 (36.5)[c](#tfn8-ppa-2-67){ref-type="table-fn"}   56.6[b](#tfn7-ppa-2-67){ref-type="table-fn"}   245.1 (142.2)[c](#tfn8-ppa-2-67){ref-type="table-fn"}    48.5[c](#tfn8-ppa-2-67){ref-type="table-fn"}
                               52.0 (37.9)                                           34.5                                           173.9 (144.5)                                            22.7
  QUE vs HAL                   66.2 (37.0)[b](#tfn7-ppa-2-67){ref-type="table-fn"}   51.8[a](#tfn6-ppa-2-67){ref-type="table-fn"}   230.2 (145.2)[a](#tfn6-ppa-2-67){ref-type="table-fn"}    45.5[a](#tfn6-ppa-2-67){ref-type="table-fn"}
                               52.0 (37.9)                                           34.5                                           173.9 (144.5)                                            22.7

**Sample size:** Haloperidol n = 110; OLZ n = 347; RIS n = 235; QUE n = 112; CLO n = 74.

Adherent defined as MPR ≥ 80%; Persistent defined as completing 1 year of treatment on the index drug.

Significant groups difference at p \< 0.05.

Significant groups difference at p \< 0.01.

Significant groups difference at p \< 0.001.

**Abbreviations:** MPR, medication possession ratio; CLO, clozapine; HAL, haloperidol; OLZ, olanzapine; QUE, quetiapine; RIS, risperidone.

###### 

Differences between treatment groups on proportion of adherent patients using 8 different MPR thresholds to define adherence

  Treatment groups             MPR threshold (%)                                                                                                                                                                                                                                                                                                                               
  ---------------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- -----------------------------------------------
  Atypicals, combined vs HAL   67.7[c](#tfn13-ppa-2-67){ref-type="table-fn"}   66.0[c](#tfn13-ppa-2-67){ref-type="table-fn"}   64.1[c](#tfn13-ppa-2-67){ref-type="table-fn"}   62.8[c](#tfn13-ppa-2-67){ref-type="table-fn"}   61.1[c](#tfn13-ppa-2-67){ref-type="table-fn"}   59.2[c](#tfn13-ppa-2-67){ref-type="table-fn"}   57.8[c](#tfn13-ppa-2-67){ref-type="table-fn"}   56.5[c](#tfn13-ppa-2-67){ref-type="table-fn"}
                               42.7                                            41.8                                            38.2                                            37.3                                            34.5                                            29.1                                            29.1                                            24.5
  OLZ vs RIS                   70.9                                            69.2[a](#tfn11-ppa-2-67){ref-type="table-fn"}   67.1[a](#tfn11-ppa-2-67){ref-type="table-fn"}   65.4[a](#tfn11-ppa-2-67){ref-type="table-fn"}   63.7[a](#tfn11-ppa-2-67){ref-type="table-fn"}   62.2[a](#tfn11-ppa-2-67){ref-type="table-fn"}   60.8[a](#tfn11-ppa-2-67){ref-type="table-fn"}   58.8
                               64.7                                            62.1                                            59.6                                            58.3                                            56.6                                            54                                              53.2                                            51.9
  OLZ vs QUE                   70.9[b](#tfn12-ppa-2-67){ref-type="table-fn"}   69.2[a](#tfn11-ppa-2-67){ref-type="table-fn"}   67.1[a](#tfn11-ppa-2-67){ref-type="table-fn"}   65.4[a](#tfn11-ppa-2-67){ref-type="table-fn"}   63.7[a](#tfn11-ppa-2-67){ref-type="table-fn"}   62.2[a](#tfn11-ppa-2-67){ref-type="table-fn"}   60.8[a](#tfn11-ppa-2-67){ref-type="table-fn"}   58.8[a](#tfn11-ppa-2-67){ref-type="table-fn"}
                               56.3                                            56.3                                            54.5                                            54.5                                            51.8                                            49.1                                            46.4                                            46.4
  RIS vs QUE                   64.7                                            62.1                                            59.6                                            58.3                                            56.6                                            54                                              53.2                                            51.9
                               56.3                                            56.3                                            54.5                                            54.5                                            51.8                                            49.1                                            46.4                                            46.4
  CLO vs HAL                   79.7[c](#tfn13-ppa-2-67){ref-type="table-fn"}   78.4[c](#tfn13-ppa-2-67){ref-type="table-fn"}   78.4[c](#tfn13-ppa-2-67){ref-type="table-fn"}   77[c](#tfn13-ppa-2-67){ref-type="table-fn"}     77[c](#tfn13-ppa-2-67){ref-type="table-fn"}     77[c](#tfn13-ppa-2-67){ref-type="table-fn"}     75.7[c](#tfn13-ppa-2-67){ref-type="table-fn"}   75.7[c](#tfn13-ppa-2-67){ref-type="table-fn"}
                               42.7                                            41.8                                            38.2                                            37.3                                            34.5                                            29.1                                            29.1                                            24.5
  CLO vs RIS                   79.7[a](#tfn11-ppa-2-67){ref-type="table-fn"}   78.4[a](#tfn11-ppa-2-67){ref-type="table-fn"}   78.4[a](#tfn11-ppa-2-67){ref-type="table-fn"}   77[b](#tfn12-ppa-2-67){ref-type="table-fn"}     77[b](#tfn12-ppa-2-67){ref-type="table-fn"}     77[b](#tfn12-ppa-2-67){ref-type="table-fn"}     75.7[b](#tfn12-ppa-2-67){ref-type="table-fn"}   75.7[b](#tfn12-ppa-2-67){ref-type="table-fn"}
                               64.7                                            62.1                                            59.6                                            58.3                                            56.6                                            54                                              53.2                                            51.9
  CLO vs OLZ                   79.7                                            78.4                                            78.4                                            77                                              77                                              77                                              75.7                                            75.7[a](#tfn11-ppa-2-67){ref-type="table-fn"}
                               70.9                                            69.2                                            67.1                                            65.4                                            63.7                                            62.2                                            60.8                                            58.8
  CLO vs QUE                   79.7[b](#tfn12-ppa-2-67){ref-type="table-fn"}   78.4[a](#tfn11-ppa-2-67){ref-type="table-fn"}   78.4[b](#tfn12-ppa-2-67){ref-type="table-fn"}   77[a](#tfn11-ppa-2-67){ref-type="table-fn"}     77[b](#tfn12-ppa-2-67){ref-type="table-fn"}     77[b](#tfn12-ppa-2-67){ref-type="table-fn"}     75.7[b](#tfn12-ppa-2-67){ref-type="table-fn"}   75.7[b](#tfn12-ppa-2-67){ref-type="table-fn"}
                               56.3                                            56.3                                            54.5                                            54.5                                            51.8                                            49.1                                            46.4                                            46.4

**Sample size:** Haloperidol n = 110; OLZ n = 347; RIS n = 235; QUE n = 112; CLO n = 74.

Significant groups difference at p \< 0.05.

Significant groups difference at p \< 0.01.

Significant groups difference at p \< 0.001.

**Abbreviations:** MPR, medication possession ratio; CLO, clozapine; HAL, haloperidol; OLZ, olanzapine; QUE, quetiapine; RIS, risperidone.
